胎盘生长因子单独或联合可溶性fms样酪氨酸激酶-1或母体因素在无症状孕妇中筛查中晚期子痫前期的准确性:系统综述与Meta分析
该系统综述与Meta分析检索1985年至2021年多个数据库,纳入100项研究进行定性合成、32项进行定量合成,评估孕中晚期无症状单胎孕妇中胎盘生长因子单独、与可溶性fms样酪氨酸激酶-1比值或联合母体因素模型预测子痫前期的诊断准确性。孕中期胎盘生长因子联合母体因素模型对早发型子痫前期的诊断比值比最高(63.20,95%CI 37.62-106.16),优于比值(6.96)和单独检测(5.62);孕晚期该模型对任意型子痫前期的预测优于单独检测但类似比值。研究间异质性大,亟需标准化研究。
要点
- 孕中期胎盘生长因子联合母体因素模型预测早发型子痫前期诊断比值比达63.20,优于单独检测和比值。
- 孕晚期该模型预测任意型子痫前期优于单独检测(27.12 vs 10.31),但与比值类似(27.12 vs 14.94)。
- 纳入研究异质性大,作者认为亟需统一模型开展标准化研究。
核心结论
- 孕中期胎盘生长因子联合母体因素±其他生物标志物对总人群早发型子痫前期预测性能最佳。
- 孕晚期该模型对任意型子痫前期的预测优于单独检测但类似可溶性fms样酪氨酸激酶-1与胎盘生长因子比值。
- 通过本Meta分析识别出大量异质性研究,亟需开发标准化研究以准确预测子痫前期。
- 识别高危患者可能有利于加强监测和分娩时机选择。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、CENTRAL、ClinicalTrials.gov和世界卫生组织国际临床试验注册平台数据库,时间为1985年1月1日至2021年4月15日。
- 纳入标准为无症状单胎孕妇孕周>18周、有子痫前期风险、报告子痫前期结局的队列或横断面诊断准确性研究,随访率>85%,可制2×2表。
- 研究方案注册于国际前瞻性系统综述注册库(CRD 42020162460)。
- 最终纳入100项研究进行定性合成、32项进行定量合成。
- 采用QUADAS-2工具评价纳入研究质量。
主要发现
- 孕中期有23项研究报告胎盘生长因子检测预测子痫前期的性能,包括单独检测16项(27个条目)、比值9项(19个条目)、基于胎盘生长因子模型6项(16个条目)。
- 孕晚期有14项研究报告胎盘生长因子检测预测子痫前期的性能,包括单独检测10项(18个条目)、比值8项(12个条目)、基于胎盘生长因子模型7项(12个条目)。
- 孕中期总人群早发型子痫前期诊断比值比:基于胎盘生长因子模型63.20(95%CI 37.62-106.16)vs 比值6.96(95%CI 1.76-27.61)vs 单独检测5.62(95%CI 3.04-10.38)。
- 孕中期非选择人群任意型子痫前期诊断比值比:基于胎盘生长因子模型28.45(95%CI 13.52-59.85)vs 单独检测7.09(95%CI 3.74-13.41)。
- 孕晚期任意型子痫前期诊断比值比:基于胎盘生长因子模型27.12(95%CI 21.67-33.94)vs 单独检测10.31(95%CI 7.41-14.35)vs 比值14.94(95%CI 9.42-23.70)。
临床怎么用
- 作者认为孕中期胎盘生长因子联合母体因素±其他生物标志物对早发型子痫前期预测性能最佳。
- 作者认为识别高危患者可能有利于加强监测和分娩时机选择。
局限性
- 通过本Meta分析识别出大量异质性研究。
- 作者认为亟需开发标准化研究,使用相同模型联合血清胎盘生长因子与母体因素±其他生物标志物以准确预测子痫前期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to: (1) identify all relevant studies reporting on the diagnostic accuracy of maternal circulating placental growth factor) alone or as a ratio with soluble fms-like tyrosine kinase-1), and of placental growth factor-based models (placental growth factor combined with maternal factors±other biomarkers) in the second or third trimester to predict subsequent development of preeclampsia in asymptomatic women; (2) estimate a hierarchical summary receiver-operating characteristic curve for studies reporting on the same test but different thresholds, gestational ages, and populations; and (3) select the best method to screen for preeclampsia in asymptomatic women during the second and third trimester of pregnancy by comparing the diagnostic accuracy of each method. DATA SOURCES: A systematic search was performed through MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform databases from January 1, 1985 to April 15, 2021. STUDY ELIGIBILITY CRITERIA: Studies including asymptomatic singleton pregnant women at >18 weeks' gestation with risk of developing preeclampsia were evaluated. We included only cohort or cross-sectional test accuracy studies reporting on preeclampsia outcome, allowing tabulation of 2×2 tables, with follow-up available for >85%, and evaluating performance of placental growth factor alone, soluble fms-like tyrosine kinase-1- placental growth factor ratio, or placental growth factor-based models. The study protocol was registered on the International Prospective Register Of Systematic Reviews (CRD 42020162460). METHODS: Because of considerable intra- and interstudy heterogeneity, we computed the hierarchical summary receiver-operating characteristic plots and derived diagnostic odds ratios, β, θi, and Λ for each method to compare performances. The quality of the included studies was evaluated by the QUADAS-2 tool. RESULTS: The search identified 2028 citations, from which we selected 474 studies for detailed assessment of the full texts. Finally, 100 published studies met the eligibility criteria for qualitative and 32 for quantitative syntheses. Twenty-three studies reported on performance of placental growth factor testing for the prediction of preeclampsia in the second trimester, including 16 (with 27 entries) that reported on placental growth factor test alone, 9 (with 19 entries) that reported on the soluble fms-like tyrosine kinase-1-placental growth factor ratio, and 6 (16 entries) that reported on placental growth factor-based models. Fourteen studies reported on performance of placental growth factor testing for the prediction of preeclampsia in the third trimester, including 10 (with 18 entries) that reported on placental growth factor test alone, 8 (with 12 entries) that reported on soluble fms-like tyrosine kinase-1-placental growth factor ratio, and 7 (with 12 entries) that reported on placental growth factor-based models. For the second trimester, Placental growth factor-based models achieved the highest diagnostic odds ratio for the prediction of early preeclampsia in the total population compared with placental growth factor alone and soluble fms-like tyrosine kinase-1-placental growth factor ratio (placental growth factor-based models, 63.20; 95% confidence interval, 37.62-106.16 vs soluble fms-like tyrosine kinase-1-placental growth factor ratio, 6.96; 95% confidence interval, 1.76-27.61 vs placental growth factor alone, 5.62; 95% confidence interval, 3.04-10.38); placental growth factor-based models had higher diagnostic odds ratio than placental growth factor alone for the identification of any-onset preeclampsia in the unselected population (28.45; 95% confidence interval, 13.52-59.85 vs 7.09; 95% confidence interval, 3.74-13.41). For the third trimester, Placental growth factor-based models achieved prediction for any-onset preeclampsia that was significantly better than that of placental growth factor alone but similar to that of soluble fms-like tyrosine kinase-1-placental growth factor ratio (placental growth factor-based models, 27.12; 95% confidence interval, 21.67-33.94 vs placental growth factor alone, 10.31; 95% confidence interval, 7.41-14.35 vs soluble fms-like tyrosine kinase-1-placental growth factor ratio, 14.94; 95% confidence interval, 9.42-23.70). CONCLUSION: Placental growth factor with maternal factors ± other biomarkers determined in the second trimester achieved the best predictive performance for early preeclampsia in the total population. However, in the third trimester, placental growth factor-based models had predictive performance for any-onset preeclampsia that was better than that of placental growth factor alone but similar to that of soluble fms-like tyrosine kinase-1-placental growth factor ratio. Through this meta-analysis, we have identified a large number of very heterogeneous studies. Therefore, there is an urgent need to develop standardized research using the same models that combine serum placental growth factor with maternal factors ± other biomarkers to accurately predict preeclampsia. Identification of patients at risk might be beneficial for intensive monitoring and timing delivery.
引用
- Chaemsaithong P, Gil MM, Chaiyasit N, et al. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023. PMID: 36990308. doi:10.1016/j.ajog.2023.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。